The estimated Net Worth of Paul G Chaney is at least $1.62 Milione dollars as of 2 June 2017. Mr. Chaney owns over 17,570 units of AB Active ETFs Inc stock worth over $1,524,648 and over the last 10 years he sold EYEG stock worth over $0. In addition, he makes $93,685 as Independent Chairman of the Board at AB Active ETFs Inc.
Paul has made over 2 trades of the AB Active ETFs Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 17,570 units of EYEG stock worth $11,421 on 2 June 2017.
The largest trade he's ever made was exercising 17,570 units of AB Active ETFs Inc stock on 2 June 2017 worth over $11,421. On average, Paul trades about 1,727 units every 56 days since 2015. As of 2 June 2017 he still owns at least 41,229 units of AB Active ETFs Inc stock.
You can see the complete history of Mr. Chaney stock trades at the bottom of the page.
Paul G. Chaney serves as Independent Chairman of the Board of the Company. He has served as a director since September 2007. He is co-founder, President & CEO of PanOptica, Inc, a private venture-backed biopharmaceutical company that licenses and develops drugs for the treatment of important ophthalmic conditions, and has held such positions since March 2009. Prior to founding PanOptica, Mr. Chaney was Executive Vice President and President of OSI-Eyetech Pharmaceuticals Inc., the wholly-owned eyecare biopharmaceutical subsidiary of OSI Pharmaceuticals, Inc. (OSI).. Prior to its acquisition by OSI,, Mr. Chaney served as Chief Operating Officer of Eyetech, Inc., where he was responsible for the launch of Macugen, the first anti-VEGF treatment for neovascular age-related macular degeneration (wet-AMD), and was part of the executive team which led Eyetech’s initial public offering in 2004. Mr. Chaney has over 30 years of experience in the biopharmaceutical and ophthalmic medical device industry, including a variety of senior management positions at Pharmacia Corporation. He began his career as a sales representative for The Upjohn Company in 1980. Mr. Chaney has also served as a member of the board of directors of Sesen Bio, Inc. (formerly Eleven Biotherapeutics, Inc.), a biologics company focusing on targeted protein therapeutics, from February 2014 to August 2018. Mr. Chaney earned a double BA in English and Biological Sciences from the University of Delaware.
As the Independent Chairman of the Board of AB Active ETFs Inc, the total compensation of Paul Chaney at AB Active ETFs Inc is $93,685. There are 3 executives at AB Active ETFs Inc getting paid more, with Stephen From having the highest compensation of $601,340.
Paul Chaney is 62, he's been the Independent Chairman of the Board of AB Active ETFs Inc since 2007. There are 2 older and 7 younger executives at AB Active ETFs Inc. The oldest executive at AB Active ETFs Inc is Morton Goldberg, 82, who is the Independent Director.
Paul's mailing address filed with the SEC is C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM, MA, 02452.
Over the last 10 years, insiders at AB Active ETFs Inc have traded over $15,523,641 worth of AB Active ETFs Inc stock and bought 17,254,349 units worth $18,625,708 . The most active insiders traders include Capital, Llc Armistice Capi..., Peter Greenleaf e (Innoven Partenaires S.A.) .... On average, AB Active ETFs Inc executives and independent directors trade stock every 60 days with the average trade being worth of $19,985,138. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 30 July 2021, trading 260,963 units of EYEG stock currently worth $647,188.
AB Active ETFs Inc executives and other stock owners filed with the SEC include: